Jennifer Roth

Title: Innovations by Jennifer Roth in Angiogenesis Inhibition

Introduction

Jennifer Roth is an accomplished inventor based in North Babylon, NY (US). She has made significant contributions to the field of medical research, particularly in the area of angiogenesis inhibition. With a total of 3 patents to her name, her work has the potential to impact therapeutic treatments for various diseases.

Latest Patents

Among her latest patents are CLK-peptide and SLK-peptide. These inventions describe methods for inhibiting angiogenesis in tissues by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV. This binding occurs with substantially greater affinity than to the native triple helical form of collagen type-IV. The methods outlined in her patents include therapeutic treatments for tumor growth, tumor metastasis, and restenosis. Additionally, these antagonists can serve as diagnostic markers of angiogenesis in both normal and diseased tissues, both in vivo and ex vivo. Furthermore, her inventions detail methods for treating tumors using these antagonists in combination with radiation therapy.

Career Highlights

Jennifer Roth is affiliated with New York University, where she continues her research and development in the field of angiogenesis. Her innovative approaches have garnered attention and recognition within the scientific community.

Collaborations

Some of her notable coworkers include Peter C Brooks and Abebe Akalu, who have collaborated with her on various research projects.

Conclusion

Jennifer Roth's contributions to the field of angiogenesis inhibition through her patents demonstrate her commitment to advancing medical science. Her work has the potential to lead to significant improvements in cancer treatment and diagnostics.